×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
JNJ – johnson & johnson (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
JNJ
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/22
11:23 am
jnj
Health Canada issues NOC to J&J's CARVYKTI for multiple myeloma [Yahoo! Finance]
Low
Report
Health Canada issues NOC to J&J's CARVYKTI for multiple myeloma [Yahoo! Finance]
11/22
09:45 am
jnj
340B Legal Challenges Highlight The Appetite For Innovation That Supports The Program's Goals [Forbes]
Low
Report
340B Legal Challenges Highlight The Appetite For Innovation That Supports The Program's Goals [Forbes]
11/22
08:42 am
jnj
Antihistamine Drugs Industry Report 2025-2030: A $381 Million Opportunity - Johnson & Johnson, Sanofi, Pfizer, and Bayer Experiencing Notable Growth Driven by Substantial R&D Investments [Yahoo! Finance]
Low
Report
Antihistamine Drugs Industry Report 2025-2030: A $381 Million Opportunity - Johnson & Johnson, Sanofi, Pfizer, and Bayer Experiencing Notable Growth Driven by Substantial R&D Investments [Yahoo! Finance]
11/22
08:11 am
jnj
Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor [Yahoo! Finance]
Low
Report
Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor [Yahoo! Finance]
11/22
08:00 am
jnj
Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor
Low
Report
Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor
11/22
07:38 am
jnj
Johnson & Johnson (NYSE:JNJ) Stock Goes Ex-Dividend In Just Three Days [Yahoo! Finance]
Low
Report
Johnson & Johnson (NYSE:JNJ) Stock Goes Ex-Dividend In Just Three Days [Yahoo! Finance]
11/22
06:39 am
jnj
Lung Cancer Surgery Market 2024 to 2034 Projected to Reach USD 2.5 Billion by 2034 with 5.7% CAGR | Future Market Insights, Inc. [Yahoo! Finance]
Low
Report
Lung Cancer Surgery Market 2024 to 2034 Projected to Reach USD 2.5 Billion by 2034 with 5.7% CAGR | Future Market Insights, Inc. [Yahoo! Finance]
11/21
04:11 pm
jnj
Health Canada Authorizes CARVYKTI® (ciltacabtagene autoleucel) for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy [Yahoo! Finance]
Low
Report
Health Canada Authorizes CARVYKTI® (ciltacabtagene autoleucel) for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/13
04:46 pm
jnj
Form 13F-HR JOHNSON & JOHNSON For: Sep 30
Low
Report
Form 13F-HR JOHNSON & JOHNSON For: Sep 30
11/6
09:24 am
jnj
Form 25-NSE JOHNSON & JOHNSON Filed by: NEW YORK STOCK EXCHANGE LLC
Low
Report
Form 25-NSE JOHNSON & JOHNSON Filed by: NEW YORK STOCK EXCHANGE LLC
10/31
05:58 pm
jnj
Form 4/A JOHNSON & JOHNSON For: May 01 Filed by: REED JOHN C
Low
Report
Form 4/A JOHNSON & JOHNSON For: May 01 Filed by: REED JOHN C
10/23
04:03 pm
jnj
Form 10-Q JOHNSON & JOHNSON For: Sep 29
Low
Report
Form 10-Q JOHNSON & JOHNSON For: Sep 29
10/21
06:18 pm
jnj
Form 4 JOHNSON & JOHNSON For: May 22 Filed by: Wolk Joseph J
Low
Report
Form 4 JOHNSON & JOHNSON For: May 22 Filed by: Wolk Joseph J
10/15
04:39 pm
jnj
Form 4 JOHNSON & JOHNSON For: Apr 25 Filed by: DAVIS D SCOTT
Low
Report
Form 4 JOHNSON & JOHNSON For: Apr 25 Filed by: DAVIS D SCOTT
10/15
07:38 am
jnj
Form 8-K JOHNSON & JOHNSON For: Oct 15
Low
Report
Form 8-K JOHNSON & JOHNSON For: Oct 15
10/9
05:07 pm
jnj
Form 3 JOHNSON & JOHNSON For: Oct 01 Filed by: Mulholland Kristen
Low
Report
Form 3 JOHNSON & JOHNSON For: Oct 01 Filed by: Mulholland Kristen
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/27
Form DEFA14A JOHNSON & JOHNSON
8.1%
3/12 Paul Harris' Top Picks: March 12, 2020 [Business News Network (BNN) Energy & Resources (Canada)] 7.5%
4/7 Is JNJ Stock A Buy On CEO's Bullish Call For Coronavirus Vaccine? [Investor's Business Daily] 4.6%
4/5 Will These 3 Coronavirus Stocks Lead the Market to Recovery? [Yahoo! Finance News] 4.3%
4/13 Stocks slip as market enters new phase, with investors worrying about balance sheets [CNBC] 4.0%
3/2 AODocs Joins AIIM Leadership Council, Showcases Innovative Approach to Information Management at 2020 AIIM Conference 3.9%
3/4 Johnson & Johnson ordered to pay $1.7 million to three Australian women in pelvic mesh class action [Reuters] 3.8%
3/18 Is This 1 Healthcare Stock Coronavirus-Proof? [The Motley Fool] 3.8%
3/24 What Technology And Manufacturing Can Do To Help Against COVID-19 [Forbes] 3.6%
4/1 5 of the Best Stocks to Buy for April [Yahoo! Finance News] 3.3%
3/12 Paul Harris' Top Picks: March 12, 2020 [Business News Network (BNN) Energy & Resources (Canada)] 7.5%
4/7 Is JNJ Stock A Buy On CEO's Bullish Call For Coronavirus Vaccine? [Investor's Business Daily] 4.6%
4/5 Will These 3 Coronavirus Stocks Lead the Market to Recovery? [Yahoo! Finance News] 4.3%
4/13 Stocks slip as market enters new phase, with investors worrying about balance sheets [CNBC] 4.0%
3/2 AODocs Joins AIIM Leadership Council, Showcases Innovative Approach to Information Management at 2020 AIIM Conference 3.9%
3/4 Johnson & Johnson ordered to pay $1.7 million to three Australian women in pelvic mesh class action [Reuters] 3.8%
3/18 Is This 1 Healthcare Stock Coronavirus-Proof? [The Motley Fool] 3.8%
3/24 What Technology And Manufacturing Can Do To Help Against COVID-19 [Forbes] 3.6%
4/1 5 of the Best Stocks to Buy for April [Yahoo! Finance News] 3.3%
TOP News Decliners
3/21
Johnson and Johnson: A Safe Haven in Recession [The Motley Fool]
-7.3%
3/20 Is Johnson & Johnson (NYSE:JNJ) Trading At A 35% Discount? [Yahoo! Finance News] -6.9%
3/10 J&J MET antibody nabs accelerated review status for certain lung cancer patients [Seeking Alpha] -6.8%
3/18 J&J files U.S. application for MS med ponesimod [Seeking Alpha] -6.6%
10/18 Wolves In Sheep’s Clothing: We Can’t Trust Businesses To Do Right By Americans Now [Forbes] -6.4%
5/28 Oklahoma taking on Johnson & Johnson in historic trial [MSNBC.com] -6.1%
3/13 Americans rush to stock up on essentials as coronavirus spreads [Reuters] -5.5%
3/11 Desperate to exit, a $10B price tag for Magic Leap is crazy [TechCrunch Blog] -4.9%
7/12 Johnson & Johnson (NYSE: JNJ) is now covered by analysts at Credit Suisse Group AG. They set an "outperform" rating and a $156.00 price target on the stock. -4.5%
3/6 Eyecare industry leaders sign Proclamation to focus on key issues facing the future of optometry -3.8%
3/20 Is Johnson & Johnson (NYSE:JNJ) Trading At A 35% Discount? [Yahoo! Finance News] -6.9%
3/10 J&J MET antibody nabs accelerated review status for certain lung cancer patients [Seeking Alpha] -6.8%
3/18 J&J files U.S. application for MS med ponesimod [Seeking Alpha] -6.6%
10/18 Wolves In Sheep’s Clothing: We Can’t Trust Businesses To Do Right By Americans Now [Forbes] -6.4%
5/28 Oklahoma taking on Johnson & Johnson in historic trial [MSNBC.com] -6.1%
3/13 Americans rush to stock up on essentials as coronavirus spreads [Reuters] -5.5%
3/11 Desperate to exit, a $10B price tag for Magic Leap is crazy [TechCrunch Blog] -4.9%
7/12 Johnson & Johnson (NYSE: JNJ) is now covered by analysts at Credit Suisse Group AG. They set an "outperform" rating and a $156.00 price target on the stock. -4.5%
3/6 Eyecare industry leaders sign Proclamation to focus on key issues facing the future of optometry -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: